FDA Approves Amivantamab-Vmjw With Carboplatin and Pemetrexed for Non-Small Cell Lung Cancer With Egfr Exon 19 Deletions or L858R Mutations
FDA批准Amivantamab-Vmjw聯合卡鉑和培美曲塞治療EGFR外顯子19缺失或L858R突變的非小細胞肺癌
FDA Approves Amivantamab-Vmjw With Carboplatin and Pemetrexed for Non-Small Cell Lung Cancer With Egfr Exon 19 Deletions or L858R Mutations
FDA批准Amivantamab-Vmjw聯合卡鉑和培美曲塞治療EGFR外顯子19缺失或L858R突變的非小細胞肺癌
譯文內容由第三人軟體翻譯。